Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994832 · ClinicalTrials.gov registry record · NA
Using Visual Arrays to Support Understanding of Genetic Risk
A NA study, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- NA
- Development phase
- 1,045
- Enrollment target
NCT06994832: Completed NA study, sponsored by Stephanie B. Seminara, MD.
NCT06994832 is a NA study that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 1,045 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06994832, a NA study, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,045 participants
- Enrollment target
Study Summary
The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims to answer are: 1. Which visual aid most accurately show genetic risk? 2. How do people perceive risk related to genetic test results? 3. What factors are associated with people discussing their results with family? Participants will: 1. receive of of two visual aids showing risk 2. state their estimation of risk 3. answer questions about how they feel about risk and sharing information with family
Primary Outcome
closest approximation to risk percentage depicted in the visual array
Interventions
- BEHAVIORAL Visual Array
- BEHAVIORAL Narrative Visual Array
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,045 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2025-08-18 |
| Phase | NA |
What the finished NCT06994832 record still lists
NCT06994832 is an interventional study that assigns participants to a tested intervention. Its 1,045 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which Visual Array is the first listed.
NCT06994832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06994832 about?
NCT06994832 is a clinical study titled "Using Visual Arrays to Support Understanding of Genetic Risk". The goal of this study is to understand how people understand risk from genetic testing. The investigators want to understand what visual aid best helps people accurately assess risk. The investigators also want to understand how people relate risk to their health. The main questions the study aims ...
What is the current status of trial NCT06994832?
This trial is currently completed. It is a NA study. The enrollment target is 1,045 participants. The study started on 2025-07-28. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT06994832?
The interventions under investigation include: Visual Array (BEHAVIORAL), Narrative Visual Array (BEHAVIORAL).
Who is sponsoring clinical trial NCT06994832?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06994832's enrollment target sits among peer trials
1,045 100th of 2000 higher than 1,901 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI